Clinical Trial Update: Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing bronchodilator efficacy of formoterol/budesonide 12/400 mcg via Discair in COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol/Budesonide 12/400 mcg via Discair (formoterol/budesonide)

Snippet

Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Conditions: Copd | Phase 4 | Status: COMPLETED